Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?
Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Stock market today: Nasdaq edges back from its record as chip companies and Eli Lilly slump
U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company ...
Eli Lilly isn't selling as much Zepbound as expected — and the stock is sinking
Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...
Eli Lilly Stock Plummets As Zepbound, Mounjaro Sales Miss Estimates
Eli Lilly stock fell sharply after the drug maker posted quarterly earnings that missed analysts’ expectations. The company ...
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...
Eli Lilly plans to begin advertising weight-loss drug Zepbound
Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...
Eli Lilly had a strong Q3, so why is its stock falling?
Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook ...